FUNDAMENTAL AND CLINICAL STUDIES ON BRL 28500 IN THE SURGICAL FIELD

• Published in: CHEMOTHERAPY Vol. 34; no. Supplement4; pp. 787 - 798
• Main Authors: YOKOYAMA, ISAO, SAITO, TOSHIAKI, HANATANI, YUJI, ARAI, TAKEYUKI
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1986; 公益社団法人 日本化学療法学会
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.34.Supplement4_787

A new antibacterial agent, BRL 28500 (clavulanic acid-ticarcillin), was studied fundamentally and clinically. The results were as follows: 1) Transfer into serum and bile: BRL 28500 (3.2g) was administered by drip infusion to four patients with surgical bile fistula, three patients with T-tube drainage and one patient with PTCdrainage, and serum and bile concentrations were determined. The levels in serum and bile reached peak concentrations of TIPC of 103.2±30.9μg/ml and 60.6±25.2μg/ml, and CVA concentrations of 4.2±0.9μg/ml and 2.0±2.5μg/ml respectively. 2) Transfer into serum and wound exudate: BRL 28500 (3.2g) was administered by drip infusion to seven patients who had undergone radical mastectomy. The levels of agent detected in serum and wound exudate reached peak concentrations of 69.9±12.9μg/ml and 31.4±19.8μg/ml (TIPC), and 1.7±1.1μg/ml and 0.9±0.7μg/ml (CVA) respectively. 3) Twenty-one patients with surgical infections were treated with BRL 28500 (3.2g) by drip infusion. The clinical efficacy of the treatment was assessed as excellent in 1, good in 10, fair in 7 and poor in 3 patients. And an overall efficacy rate was 52.4%. No side effects were observed.